Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Mar;13(3):387–391. doi: 10.1111/j.1365-2125.1982.tb01390.x

Effect of rifampicin on metoprolol and antipyrine kinetics.

P N Bennett, V A John, V B Whitmarsh
PMCID: PMC1402102  PMID: 7059439

Abstract

1 Effects of rifampicin on the pharmacokinetics of single oral doses of metoprolol and antipyrine are reported. 2 Rifampicin, administered daily for 15 days, reduced the area under the plasma concentration-time curve (AUC) of metoprolol but the rate constant for elimination (beta) of metoprolol from plasma did not alter significantly. 3 Administration of rifampicin for 13 days reduced AUC and increased beta of antipyrine. Thirteen days after discontinuing rifampicin. AUC and beta of antipyrine remained significantly different from the initial values. 4 Some loss of beta-adrenoceptor blockade should be anticipated if rifampicin is administered to patients who are receiving metoprolol.

Full text

PDF
387

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arfwidsson A., Borg K. O., Hoffmann K. J., Skånberg I. Metabolism of metoprolol in the rat in vitro and in vivo. Xenobiotica. 1976 Nov;6(11):691–711. doi: 10.3109/00498257609151681. [DOI] [PubMed] [Google Scholar]
  2. Borg K. O., Carlsson E., Hoffmann K. J., Jönsson T. E., Thorin H., Wallin B. Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):125–135. doi: 10.1111/j.1600-0773.1975.tb03329.x. [DOI] [PubMed] [Google Scholar]
  3. Breckenridge A., Orme M. L., Davies L., Thorgeirsson S. S., Davies D. S. Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514–520. doi: 10.1002/cpt1973144part1514. [DOI] [PubMed] [Google Scholar]
  4. Brodie M. J., Boobis A. R., Dollery C. T., Hillyard C. J., Brown D. J., MacIntyre I., Park B. K. Rifampicin and vitamin D metabolism. Clin Pharmacol Ther. 1980 Jun;27(6):810–814. doi: 10.1038/clpt.1980.115. [DOI] [PubMed] [Google Scholar]
  5. Degen P. H., Riess W. Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography. J Chromatogr. 1976 Jun 9;121(1):72–75. doi: 10.1016/s0021-9673(00)82299-2. [DOI] [PubMed] [Google Scholar]
  6. Haglund K., Seideman P., Collste P., Borg K. O., von Bahr C. Influence of pentobarbital on metoprolol plasma levels. Clin Pharmacol Ther. 1979 Sep;26(3):326–329. doi: 10.1002/cpt1979263326. [DOI] [PubMed] [Google Scholar]
  7. Johnsson G., Regårdh C. G., Sölvell L. Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):31–44. doi: 10.1111/j.1600-0773.1975.tb03320.x. [DOI] [PubMed] [Google Scholar]
  8. Miguet J. P., Mavier P., Soussy C. J., Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology. 1977 May;72(5 Pt 1):924–926. [PubMed] [Google Scholar]
  9. Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
  10. Prescott L. F., Adjepon-Yamoah K. K., Roberts E. Rapid gas-liquid chromatographic estimation of antipyrine in plasma. J Pharm Pharmacol. 1973 Mar;25(3):205–207. doi: 10.1111/j.2042-7158.1973.tb10625.x. [DOI] [PubMed] [Google Scholar]
  11. Regårdh C. G., Johnsson G., Jordö L., Sölvell L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):45–58. doi: 10.1111/j.1600-0773.1975.tb03321.x. [DOI] [PubMed] [Google Scholar]
  12. Rowland M. Influence of route of administration on drug availability. J Pharm Sci. 1972 Jan;61(1):70–74. doi: 10.1002/jps.2600610111. [DOI] [PubMed] [Google Scholar]
  13. Toverud E. L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Whitmarsh V., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol. 1981;21(2):155–160. doi: 10.1007/BF00637517. [DOI] [PubMed] [Google Scholar]
  14. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES